The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non‑alcoholic fatty liver disease (NAFLD)
Abstract
Background: Vitamin D supplementation has been shown to decrease insulin resistance through which it might cause fatty liver. Fatty liver increasingly results in type 2 diabetes mellitus (T2DM). Insulin resistance and fatty liver are particularly closely related. The aim of present study is to examine the effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non‑alcoholic fatty liver disease (NAFLD).
Materials and Methods: This randomized placebo‑controlled clinical trial was conducted on 60 patients with NAFLD, who were divided equally into intervention and control groups. Patients in the intervention group received vitamin D3 (50,000 IU) and patients in the control group received placebo capsules every week for 10 weeks. Blood sugar, homeostatic model assessment‑insulin resistance (HOMA‑IR), and homeostatic model assessment‑beta cell (HOMA‑B) were checked at baseline and after 10 weeks of the intervention. Adjustment for variables was performed by analysis of covariance (ANCOVA).
Results: Vitamin D supplementation resulted in increased serum 25‑hydroxy vitamin D [25(OH) D] concentration in the intervention group compared to the control group [+68 (12) vs. −1.9 (2.44); P = 0.001]. Intake of vitamin D supplements led to a marginally significant decrease in fasting blood glucose [FBS: −12 (4) in the intervention group compared to − 3 (2) in the control group; P = 0.055]. Also, HOMA‑IR decreased in the intervention group compared to the control group [−1.75 (0.23) vs. 0.12 (0.41); P = 0.066].
Conclusions: Vitamin D supplementation resulted in decreased HOMA‑IR and FBS concentration in patients with NAFLD; however, it did not affect the insulin level and HOMA‑B significantly.
Keywords
Full Text:
PDFReferences
Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388‑93.
Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009;50:1282‑93.
Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132‑8.
Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002;97:2460‑2.
Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008;118:277‑83.
Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434‑8.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313‑21.
Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641‑9.
Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinic pathological correlates of pediatric non‑alcoholic fatty liver disease. J Pediatr 2003;143:500‑5.
Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39‑48.
Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose Homeostasis. Int J Endocrinol 2010;2010:351‑85.
Su Y, Ye L. Can vitamin D intake assist in improving the outcome of endodontic treatment for diabetic patients. Med Hypotheses 2010;74:673‑5.
Foss YJ. Vitamin D deficiency is the cause of common obesity. Med Hypotheses 2009;72:314‑21.
Esmaillzadeh A, Mirmiran P, Azizi F. Whole‑grain consumption and the metabolic syndrome: A favorable association in Tehranian adults. Eur J Clin Nutr 2005;59:353‑62.
Zhang Z, Zhang Z. Comment on “Vitamin D deficiency is the cause of common obesity”. Med Hypotheses 2009;73:123.
Mattila C, Knekt P, Männistö S, Rissanen H, Laaksonen MA, Montonen J, et al. Serum 25‑hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007;30:2569‑70.
Nam GE, Kim do H, Cho KH, Park YG, Han KD, Kim SM, et al. 25‑Hydroxyvitamin D insufficiency is associated with cardiometabolic risk in Korean adolescents: The 2008‑2009 Korea National Health and Nutrition Examination Survey (KNHANES). Public Health Nutr 2014;17:186‑94.
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13‑5.
Pacifico L, Anania C, Osborn JF, Ferraro F, Bonci E, Olivero E, et al. Low 25(OH) D3 levels are associated with total adiposity, metabolic syndrome, and hypertension in Caucasian children and adolescents. Eur J Endocrinol 2011;165:603‑11.
Muldowney S, Lucey AJ, Paschos G, Martinez JA, Bandarra N, Thorsdottir I, et al. Relationships between vitamin D status and cardio‑metabolic risk factors in young European adults. Ann Nutr Metab 2011;58:85‑93.
Marchesini G, Brizi M, Morselli‑Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450‑5.
Seppälä‑Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023‑8.
Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effect of metformin and troglitazone in type 2 Diabetes mellitus. N Engl J Med 1998;338:867‑72.
Pittas AG, Harris SS, Stark PC, Dawson‑Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non‑diabetic adult. Diabetes Care 2007;30:980‑6.
Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long‑term treatment with active vitamin D (alphacalcidol) in middle‑aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 1989;11:141‑7.
Witham MD, Dove FJ, Druburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D (3) on markers of vascular health in patients with type 2 diabetes: A randomised controlled trial. Diabetologia 2010;53:2112‑9.
Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, et al. Expression of 25‑hydroxyvitamin D3‑1alpha‑hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004;89‑90:121‑5.
Ojuka EO. Role of calcium AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 2004;63:275‑8.
Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator‑activated receptor δ gene is a primary target of 1α, 25‑dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005;349:248‑60.
Cohen‑Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti‑inflammatory activity of 1,25 dihydroxy vitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007;103:558‑62.
Foroughi M, Maghsoudi Z, Ghiasvand R, Iraj B, Askari G. Effect of Vitamin D Supplementation on C reactive Protein in Patients with Nonalcoholic Fatty Liver Int J Prev Med 2014;5:969-75.
Mehdi Foroughi, Zahra Maghsoudi, Gholamreza Askari. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. ABR 2015. [In press].
Mehdi Foroughi, Zahra Maghsoudi, Gholamreza Askari. The effect of vitamin D supplementation on lipid profile in patients with non-alcoholic fatty liver (NAFLD). IJNMR 2015. [In press].
Mehdi Foroughi, Zahra Maghsoudi, Gholamreza Askari. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non‑alcoholic fatty liver disease (NAFLD) IJNMR 2015. [In press]
Refbacks
- There are currently no refbacks.